7,672 results match your criteria The Annals of pharmacotherapy[Journal]


Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice.

Ann Pharmacother 2019 Mar 10:1060028019835843. Epub 2019 Mar 10.

1 West Palm Beach VA Medical Center, FL, USA.

Background: The optimal monitoring and follow-up strategy for long-term direct oral anticoagulant (DOAC) therapy has not been established. Historically, at our medical center, DOAC patients were referred to a clinical pharmacy specialist managed anticoagulation clinic (AC) for monitoring via regularly scheduled encounters (face-to-face or telephone).

Objective: To determine if implementation of a DOAC Population Management Tool (PMT) designed to identify patients who most likely require clinical review and possibly intervention, would improve the efficacy (interventions per patient) and efficiency (time invested to generate an intervention) of monitoring over AC practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835843DOI Listing
March 2019
1 Read

No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.

Ann Pharmacother 2019 Mar 6:1060028019836775. Epub 2019 Mar 6.

1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Objective: To review the literature for the treatment of classical and variant hairy cell leukemia (HCL, HCLv), evaluating efficacy, safety, and supportive care involved in the use of purine analogues (PAs), interferon, BRAF inhibitors, monoclonal antibodies, Bruton's tyrosine kinase inhibitors, and new immunotoxin, moxetumomab pasudotox-tdfk (MPT). An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox.

Study Selection And Data Extraction: Studies written in the English language were considered for this article. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019836775
Publisher Site
http://dx.doi.org/10.1177/1060028019836775DOI Listing
March 2019
2 Reads

Assessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysis.

Ann Pharmacother 2019 Mar 2:1060028019835845. Epub 2019 Mar 2.

1 University of British Columbia, Vancouver, BC, Canada.

Background: Patient education facilitates construction of a correct illness representation, improves beliefs about medications, and improves knowledge, factors that have been associated with better adherence.

Objective: Our objective was to characterize the published literature about atrial fibrillation (AF) patients' disease and medication knowledge to identify knowledge gaps and misconceptions to inform AF patient education strategies.

Methods: Following PRISMA guidelines, we searched PubMed, EMBASE, CINAHL, and PsychINFO from inception to May 2018 for studies that assessed AF patients' knowledge about their condition and medications. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019835845
Publisher Site
http://dx.doi.org/10.1177/1060028019835845DOI Listing
March 2019
2 Reads

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.

Ann Pharmacother 2019 Feb 27:1060028019835166. Epub 2019 Feb 27.

2 University of Florida College of Pharmacy, Gainesville, FL, USA.

Objective: To review the pharmacology, efficacy, and safety of the calcitonin gene-related peptide (CGRP) inhibitor erenumab for migraine preventive therapy.

Data Sources: A MEDLINE/PubMed search (January 2000 to January 2019) was conducted using the keywords erenumab-aooe, erenumab, migraine, migraine prophylaxis, migraine prevention, and chronic migraine. Additional articles were identified by hand from references. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835166DOI Listing
February 2019
1 Read

Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.

Ann Pharmacother 2019 Feb 27:1060028019833992. Epub 2019 Feb 27.

1 Sylvester Comprehensive Cancer Center, Hollywood, FL, USA.

Objective: To review the mechanism of action, clinical efficacy, safety, dosage, administration, and role of copanlisib in the treatment of relapsed follicular lymphoma (FL).

Data Sources: Sources of information were identified through searches of PubMed (August 2014 to January 2019) using the key terms copanlisib, Aliqopa, PI3K inhibitor, and BAY 80-6946. Unpublished abstract information was obtained from the American Society of Clinical Oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833992DOI Listing
February 2019

Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.

Ann Pharmacother 2019 Feb 27:1060028019835209. Epub 2019 Feb 27.

1 University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL, USA.

Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice.

Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword andexanet alfa for clinical trials. References of identified articles were searched by hand for additional citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835209DOI Listing
February 2019

Ceftaroline-Induced Thrombocytopenia: A Case Report.

Ann Pharmacother 2019 Feb 27:1060028019835208. Epub 2019 Feb 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835208DOI Listing
February 2019

Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.

Ann Pharmacother 2019 Feb 27:1060028019835202. Epub 2019 Feb 27.

2 Lexington Veterans Affairs Health Care System, Lexington, KY, USA.

Background: Lab tests such as activated partial thromboplastin time (aPTT) or anti-factor Xa (anti-Xa) levels are typically used to monitor intravenous unfractionated heparin (IV heparin), with recent evidence suggesting that anti-Xa levels may provide a more accurate measure of anticoagulation.

Objective: The Lexington Veterans Affairs Health Care System transitioned from using aPTT to anti-Xa levels in January 2017. This study was conducted to evaluate the efficacy and safety of this change. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835202DOI Listing
February 2019

Severe Peripheral Edema in a Dabigatran-Treated Patient.

Ann Pharmacother 2019 Feb 25:1060028019834634. Epub 2019 Feb 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019834634DOI Listing
February 2019

Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds.

Ann Pharmacother 2019 Feb 25:1060028019833696. Epub 2019 Feb 25.

5 Erlanger Health System, Chattanooga, TN, USA.

Background: Literature indicating clinically relevant benefits of an adjunctive somatostatin analog to standard therapies in nonvariceal upper-gastrointestinal bleeding (NVUGIB) is lacking.

Objective: The primary objective of this study was to find the association between outcomes in patients with NVUGIB treated with octreotide and a proton pump inhibitor (PPI; combination group) compared with those treated with a PPI alone.

Methods: We conducted a retrospective cohort study of adults admitted within a 5-hospital health care system with a NVUGIB treated with a PPI continuous infusion with or without an octreotide infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833696DOI Listing
February 2019

Acknowledgments to AOP Peer Reviewers November 1, 2017, to October 31, 2018.

Authors:

Ann Pharmacother 2019 Jan;53(1):107-113

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018814934DOI Listing
January 2019

Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience.

Ann Pharmacother 2019 Feb 21:1060028019829860. Epub 2019 Feb 21.

1 King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Background: The current CHEST guidelines recommend the use of antithrombotic therapy, either aspirin or warfarin, as a primary thromboembolic complications (TECs) prophylaxis in patients who undergo Fontan procedure, without specification on drug selection or duration of therapy.

Objective: To investigate the incidence rate of late TECs, occurring after 1-year post-Fontan procedure and to assess the difference in rate of late TECs between warfarin and aspirin.

Methods: A retrospective cohort study included patients who had Fontan procedures between 1985-2010 at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829860DOI Listing
February 2019
1 Read

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy.

Ann Pharmacother 2019 Feb 15:1060028019833038. Epub 2019 Feb 15.

4 Massachusetts College of Pharmacy and Health Sciences University, School of Pharmacy, Worcester, MA, USA.

Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of combination therapies.

Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and EMBASE to identify studies of malignancies in PLWH in the modern era.

Study Selection And Data Extraction: Article bibliographies and drug interaction databases were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833038DOI Listing
February 2019
2 Reads

Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.

Ann Pharmacother 2019 Feb 13:1060028019831674. Epub 2019 Feb 13.

1 Auburn University Harrison School of Pharmacy, AL, USA.

Objective: To review the efficacy and safety of dolutegravir (DTG) with rilpivirine (RPV) as a dual therapy regimen in the treatment of HIV-1 infection.

Data Sources: A literature search was performed using PubMed (1966 to January 2019) and Google Scholar (2014 to January 2019) with the search terms dolutegravir, rilpivirine, dual, and switch. Other resources included review articles and the manufacturer product label. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831674DOI Listing
February 2019
2 Reads

Intravenous Olanzapine for the Management of Agitation: Review of the Literature.

Ann Pharmacother 2019 Feb 13:1060028019831634. Epub 2019 Feb 13.

1 St John's University College of Pharmacy and Health Sciences, Queens, NY, USA.

Objective: The purpose of this review is to summarize the current evidence of the off-label use of intravenous (IV) olanzapine and discuss its risks versus benefits for the management of agitation.

Data Sources: A literature search was conducted to gather relevant data regarding IV use of olanzapine for the management of acute agitation. PubMed, EMBASE, MEDLINE, and IPA were searched using the keywords and MESH terms: olanzapine, intravenous, IV, off-label, and agitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831634DOI Listing
February 2019
2 Reads

Effect of an Asthma Question Prompt List and Video Intervention on Adolescents' Medication Adherence 12 Months Later.

Ann Pharmacother 2019 Feb 13:1060028019831259. Epub 2019 Feb 13.

1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Background: Many adolescents do not obtain the maximum benefit from their asthma medications. Improving patient-provider communication may improve adolescents' asthma knowledge, adherence, and clinical outcomes.

Objective: To determine how a question prompt list and educational video intervention affect youth- and caregiver-reported medication adherence and self-reported medication problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831259DOI Listing
February 2019

Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.

Ann Pharmacother 2019 Feb 10:1060028019830788. Epub 2019 Feb 10.

3 University of Alberta, Edmonton, AB, Canada.

Objective: To synthesize data on the pharmacokinetics and safety of dolutegravir and elvitegravir in pregnant women living with HIV.

Data Sources: A PubMed, EMBASE, Web of Science, and Google Scholar literature search (January 2010 to December 2018) was performed using the search terms dolutegravir, elvitegravir, women, pregnant*, and HIV. Additional reports were identified from conference abstracts and review of reference lists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019830788DOI Listing
February 2019
2 Reads

A Retrospective Analysis of the Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.

Ann Pharmacother 2019 Feb 8:1060028019830785. Epub 2019 Feb 8.

1 SEIREI Hamamatsu General Hospital, Naka-ku, Japan.

Background: Chemotherapy-induced neutropenia (CIN) is an important dose-limiting toxicity of chemotherapy. However, evidence suggests that the occurrence of CIN may be predictive of treatment outcome. Indeed, studies have revealed that the onset of CIN is associated with a good chemotherapeutic response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019830785DOI Listing
February 2019
1 Read

Vancomycin Versus Metronidazole for Nonsevere Clostridioides difficile Infection: Are the Data Adequate to Change Practice?

Ann Pharmacother 2019 Feb 8:1060028019829764. Epub 2019 Feb 8.

1 University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.

Objective: To compare oral metronidazole and vancomycin for the treatment of mild-to-moderate Clostridioides difficile infection (mmCDI).

Data Sources: A MEDLINE literature search (inception to November 2018) was performed using the search terms metronidazole, vancomycin, and Clostridium/Clostridioides difficile. Additional references were identified from a review of literature citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829764DOI Listing
February 2019

Evaluating the Effect of a Patient Decision Aid for Atrial Fibrillation Stroke Prevention Therapy.

Ann Pharmacother 2019 Feb 6:1060028019828420. Epub 2019 Feb 6.

1 The University of British Columbia, Vancouver, BC, Canada.

Background: Stroke prevention therapy decisions for patients with atrial fibrillation (AF) are complex and require trade-offs, but few validated patient decision aids (PDAs) are available to facilitate shared decision making.

Objective: To evaluate the effects of a novel PDA on decision-making parameters for AF patients choosing stroke prevention therapy.

Methods: We developed an evidence-based individualized online AF PDA for stroke prevention therapy and evaluated it in a prospective observational pilot study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828420DOI Listing
February 2019
2 Reads

Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.

Ann Pharmacother 2019 Feb 6:1060028019828954. Epub 2019 Feb 6.

1 Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA.

Objective: To review the pharmacology, efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval.

Data Sources: A literature search using PubMed was conducted (inception to December 2018) using the terms lofexidine, opioid, opiate, and withdrawal. References from retrieved articles and the prescribing information were reviewed for any additional material. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828954DOI Listing
February 2019

The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes.

Ann Pharmacother 2019 Feb 6:1060028019828681. Epub 2019 Feb 6.

1 Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.

Background: Dual health system use may provide increased access to physicians, medications, and other health care resources but may also increase the complexity and coordination of medication regimens. Thus, it is important to elucidate the impact of dual use on medication adherence.

Objective: The objective of this study was to evaluate the impact on medication adherence for veterans with dual health care system use (VA and Medicare) when obtaining prescription antihyperglycemic medications to treat diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828681DOI Listing
February 2019
1 Read

Impact of Quetiapine Therapy on QTc Prolongation in Critically Ill Patients.

Ann Pharmacother 2019 Feb 1:1060028019829494. Epub 2019 Feb 1.

1 University of California San Francisco Medical Center, San Francisco, CA, USA.

Background: Quetiapine is an atypical antipsychotic commonly utilized for the management of delirium in critically ill patients. The impact of quetiapine on QTc in the critically ill population is largely unknown.

Objective: The purpose of this study was to evaluate QTc prolongation following administration of quetiapine for the management of delirium in critically ill patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829494DOI Listing
February 2019
6 Reads

Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism.

Ann Pharmacother 2019 Jan 30:1060028019828423. Epub 2019 Jan 30.

2 Duke University Hospital, Durham, NC, USA.

Background: Pulmonary embolism (PE) is the associated cause of unexplained cardiac arrest in 5% to 13% of patients. Although thrombolytic agents have been studied, patient outcomes during cardiac arrest are lacking.

Objective: The purpose of this study was to describe outcomes of patients who received thrombolytic therapy during cardiac arrest for suspected or confirmed PE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828423DOI Listing
January 2019
3 Reads

Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.

Ann Pharmacother 2019 Jan 30:1060028019827852. Epub 2019 Jan 30.

1 David Grant USAF Medical Center, Travis Air Force Base, CA, USA.

Background: Dipeptidyl peptidase 4 (DPP-4) inhibitors are a popular second-line treatment for type 2 diabetes mellitus. Several studies have reported on the association between DPP-4 inhibitors and the risk of developing inflammatory bowel disease (IBD), with conflicting results.

Objective: This meta-analysis aims to elucidate the risk for IBD with DPP-4 inhibitor therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019827852DOI Listing
January 2019
4 Reads

Pharmacy-Led β-Lactam Allergy Interview (BLAI) Reduces Duration of Fluoroquinolones Within a Community Hospital.

Ann Pharmacother 2019 Jan 28:1060028019826223. Epub 2019 Jan 28.

2 St Vincent's Health System, Birmingham, AL, USA.

Background: Patients with reported β-lactam allergies often receive broad-spectrum antimicrobials and have been shown to experience a variety of negative health consequences, such as increased mortality, costs, readmission, and adverse reactions. Current literature focuses on β-lactam allergy skin testing but lacks evidence on β-lactam allergy interviews (BLAI) when skin testing is unavailable.

Objective: This study aimed to test the impact of a pharmacy-led BLAI on duration of fluoroquinolones at a community hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019826223DOI Listing
January 2019

Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.

Authors:
Tianrui Yang

Ann Pharmacother 2019 Jan 23:1060028019826565. Epub 2019 Jan 23.

1 University of Texas at Tyler Ben and Maytee Fisch College of Pharmacy, Tyler, TX, USA.

Objective: To review the pharmacology, pharmacokinetics, clinical trials, and clinical implications of baloxavir marboxil.

Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor. Additional data were obtained from the prescribing information and relevant guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019826565DOI Listing
January 2019

Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.

Ann Pharmacother 2019 Jan 17:1060028018824988. Epub 2019 Jan 17.

1 Durham Veterans Affairs Health Care System, Durham, NC, USA.

Background: Substance use disorders (SUDs) are commonly encountered in patients with chronic hepatitis C virus (HCV) infection. It is important to consider the impact of SUDs on HCV treatment.

Objective: To compare the rate of clinical cure (sustained virological response at least 12 weeks after end of therapy [SVR12]) in veterans with chronic HCV infection treated with direct-acting antivirals (DAAs) with and without ongoing or recent substance use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824988DOI Listing
January 2019
10 Reads

Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention.

Ann Pharmacother 2019 Jan 17:1060028018825140. Epub 2019 Jan 17.

1 UIC College of Pharmacy, Rockford, IL, USA.

Background: Data on aspirin for primary prevention of cardiovascular disease (CVD) are conflicting and changing as new trials are published on the subject.

Objective: To review recent data evaluating the efficacy and safety of aspirin for primary prevention of CVD.

Data Sources: Articles evaluating aspirin for primary prevention of CVD were gathered using a MEDLINE search with the keywords aspirin review, aspirin peripheral artery disease, aspirin stroke, aspirin coronary artery disease, aspirin diabetes, aspirin primary prophylaxis, and aspirin elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018825140DOI Listing
January 2019
5 Reads

Medication Histories in Critically Ill Patients Completed by Pharmacy Personnel.

Ann Pharmacother 2019 Jan 17:1060028018825483. Epub 2019 Jan 17.

1 Duke University Hospital, Durham, NC, USA.

Background: Although critically ill adults often have extended hospital lengths of stay and are at high risk of having medication-related adverse events, the value of medication histories in these patients remains underreported.

Objective: To assess the feasibility of performing medication histories in critically ill adults and to establish the frequency of and characterize identified discrepancies.

Methods: This prospective study included patients admitted to 4 intensive care units (ICUs) in a large academic medical center and was conducted in 2 phases. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028018825483
Publisher Site
http://dx.doi.org/10.1177/1060028018825483DOI Listing
January 2019
11 Reads

Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.

Ann Pharmacother 2019 Jan 16:1060028018824640. Epub 2019 Jan 16.

5 University of North Carolina Medical Center, Chapel Hill, NC, USA.

Objective: To review the efficacy and safety of perioperative administration of intravenous (IV) antiplatelet agents as a substitute for oral P2Y inhibitors and to provide clinicians guidance on optimal and cost-effective use of these medications.

Data Sources: A MEDLINE literature search (1950 to November 2018) was performed using the key search terms abciximab, bridging, cangrelor, cardiac surgery, coronary artery bypass surgery, eptifibatide, intravenous antiplatelet agent, and tirofiban. Additional references were identified from a review of literature citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824640DOI Listing
January 2019
1 Read

Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.

Ann Pharmacother 2019 Jan 13:1060028018824578. Epub 2019 Jan 13.

1 State University of New York, Binghamton, NY, USA.

Objective: We review here the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, potential drug-drug interactions and place in therapy of brigatinib for abnormal anaplastic lymphoma kinase (ALK) specific non-small-cell lung cancer (NSCLC).

Data Sources: A literature search using PubMed was conducted using the terms brigatinib and ALK positive NSCLC from January 2013 to November 2018.

Study Selection And Data Extraction: All English-language articles evaluating brigatinib were analyzed for this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824578DOI Listing
January 2019
1 Read

Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site).

Ann Pharmacother 2019 Jan 13:1060028018823330. Epub 2019 Jan 13.

1 The University of British Columbia, Vancouver, BC, Canada.

Background: Cardiovascular (CV) disease is a leading cause of death despite being largely preventable. Employers increasingly offer preventive health programs in the workplace, and pharmacists are well suited to provide these programs.

Objective: To evaluate the impact of a pharmacist-led service on CV risk in University of British Columbia (UBC) employees. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018823330DOI Listing
January 2019
8 Reads

Attempts to Limit Opioid Prescribing in Critically Ill Patients: Not So Easy, Not So Fast.

Authors:
Brian L Erstad

Ann Pharmacother 2019 Jan 13:1060028018824724. Epub 2019 Jan 13.

1 University of Arizona, Tucson, AZ, USA.

Objective: To discuss why opioids have been considered the long-standing first-line therapy for treating acute, severe nociceptive pain in critically ill patients and discuss considerations for limiting opioid overuse in the intensive care unit setting.

Data Sources: Articles were identified through searches of PubMed and EMBASE from database inception until December 2018. Additional references were located through a review of the bibliographies of articles and clinical practice guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824724DOI Listing
January 2019
2 Reads

Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Ann Pharmacother 2019 Jan 8:1060028018822124. Epub 2019 Jan 8.

1 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Objective: To review the efficacy, safety, pharmacology and pharmacokinetics of pure, plant-derived cannabidiol (CBD; Epidiolex) in the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

Data Sources: Relevant information was identified through EMBASE and Ovid MEDLINE (1946 to October 2018). Product labeling and https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018822124DOI Listing
January 2019
1 Read

Neratinib in HER2-Positive Breast Cancer Patients.

Ann Pharmacother 2019 Jan 4:1060028018824088. Epub 2019 Jan 4.

1 University of Houston College of Pharmacy, Houston, TX, USA.

Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of neratinib in human epidermal growth factor receptor (HER2)+ breast cancer (BC).

Data Sources: A PubMed search was performed using the term neratinib between September 12, 2018, and November 21, 2018. References of published articles and reviews were also assessed for additional information. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028018824088
Publisher Site
http://dx.doi.org/10.1177/1060028018824088DOI Listing
January 2019
8 Reads
2.059 Impact Factor

Systematic Review of the Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening for MRSA Pneumonia.

Ann Pharmacother 2019 Jan 2:1060028018823027. Epub 2019 Jan 2.

4 Rush University Medical Center, Chicago, IL, USA.

Objective: To describe the diagnostic performance characteristics of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening for patients with pneumonia.

Data Sources: PubMed and Scopus were searched from 1 January 1990 to 12 December 2018 using terms methicillin-resistant Staphylococcus aureus AND (screening OR active surveillance OR surveillance culture OR targeted surveillance OR chromogenic OR PCR OR polymerase chain reaction OR rapid test) AND (nares OR nasal) AND (pneumonia OR respiratory).

Study Selection And Data Extraction: Relevant studies in humans and English were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018823027DOI Listing
January 2019

Topical Tranexamic Acid for the Treatment of Acute Epistaxis: A Systematic Review and Meta-analysis.

Ann Pharmacother 2018 Dec 21:1060028018820625. Epub 2018 Dec 21.

1 Rush University Medical Center, Chicago, IL, USA.

Objective: To compare topical tranexamic acid (TXA) with control groups for the treatment of acute epistaxis assessing bleeding cessation, discharge within 2 hours, rebleeding rates, complication rates, and patient satisfaction.

Data Sources: PubMed, CINAHL, LILACS, Scopus, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched from inception to November 2018.

Study Selection And Data Extraction: All randomized controlled trials comparing topical TXA with control groups for the treatment of acute epistaxis in humans were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018820625DOI Listing
December 2018

Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial.

Ann Pharmacother 2018 Dec 21:1060028018821149. Epub 2018 Dec 21.

2 Emory University School of Medicine, Atlanta, GA, USA.

Background: Enoxaparin dosing recommendations for morbidly obese patients are lacking. Retrospective and observational studies reported goal anti-Xa levels with a median dose of 0.8 mg/kg using total body weight. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018821149DOI Listing
December 2018

Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient.

Ann Pharmacother 2018 Dec 17:1060028018817935. Epub 2018 Dec 17.

1 University of South Carolina College of Pharmacy, Columbia, SC, USA.

Objective: To review the treatment of common bacterial and viral infections occurring in the pregnant patient.

Data Sources: A literature search of MEDLINE was performed (inception to October 2018). The Centers for Disease Control and Prevention website was utilized for additional information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018817935DOI Listing
December 2018
9 Reads

Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.

Ann Pharmacother 2018 Dec 7:1060028018817904. Epub 2018 Dec 7.

3 Houston Methodist Hospital, Houston, TX, USA.

Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.

Data Sources: A PubMed search was performed using the terms 'Ribociclib', 'Kisqali', and 'LEE011' between May 2018 and November 2018. References of published articles and reviews were also assessed for additional information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018817904DOI Listing
December 2018
18 Reads
2.059 Impact Factor

Steglatro (Ertugliflozin): A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.

Ann Pharmacother 2018 Dec 7:1060028018818829. Epub 2018 Dec 7.

1 University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL, USA.

Objective: The purpose of this article is to review the pharmacological aspects of ertugliflozin and its clinical trials, which led to Food and Drug Administration (FDA) approval for the treatment of type 2 diabetes mellitus (T2DM).

Data Sources: A MEDLINE/PubMed (May 2013 to October 2018) search was conducted using the following keywords: ertugliflozin, sodium glucose co-transporter 2 inhibitor, SGLT2 inhibitor, type 2 diabetes mellitus, hyperglycemia. Study Selection and Data Extraction Quantify: We included English-language articles evaluating ertugliflozin pharmacology, pharmacokinetics, efficacy, and safety in humans for blood glucose reduction in human subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018818829DOI Listing
December 2018
1 Read

Evaluation of Intravenous Phenytoin and Fosphenytoin Loading Doses: Influence of Obesity and Sex.

Ann Pharmacother 2018 Dec 7:1060028018818785. Epub 2018 Dec 7.

3 Michigan Medicine, Ann Arbor, MI, USA.

Background: Recommended loading doses (LDs) of phenytoin and fosphenytoin range from 10 to 25 mg/kg. Few studies have examined the LD requirements in male versus female patients and in patients who are obese.

Objectives: To examine the influence of obesity and sex on phenytoin LDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018818785DOI Listing
December 2018

A Review and Assessment of Drug-Induced Thrombocytosis.

Ann Pharmacother 2018 Dec 10:1060028018819450. Epub 2018 Dec 10.

1 Southwestern Oklahoma State University, Weatherford, OK, USA.

Objectives: The purpose of this article is to review the current literature on drug-induced thrombocytosis with the goal of critically assessing causality and providing a comprehensive review of the topic. Thrombopoietic growth factors, such as thrombopoietin-receptor agonists (romiplostim and eltrombopag) and erythropoietin are not included in our review.

Data Sources: The literature search included published articles limited to the English language and humans in MEDLINE, EMBASE, and Web of Science databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018819450DOI Listing
December 2018
12 Reads

Adverse Drug Events as a Reason for Adult Hospitalization: A Nationwide Readmission Study.

Ann Pharmacother 2018 Dec 10:1060028018818571. Epub 2018 Dec 10.

1 Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Background: Adverse drug events (ADEs) are common; however, there are limited data on the impact of ADEs on post-discharge outcomes.

Objectives: To identify ADEs responsible for readmission within 6 months of hospital discharge in the United States. Secondary objectives were to examine whether demographic, clinical, and hospital characteristics were associated with ADE readmission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018818571DOI Listing
December 2018

Dexmedetomidine Use in a Tertiary Care NICU: A Descriptive Study.

Ann Pharmacother 2018 Dec 3:1060028018812089. Epub 2018 Dec 3.

2 Department of Peditrics, University of Calgary, Calgary, AB, Canada.

Background: Continuous infusions of dexmedetomidine are increasingly used for sedation in critically ill pediatric patients. Emerging data suggest potential benefits when used for sedation in neonates, including reduced sedative requirements and earlier enteral feeds.

Objective: To describe the use, adverse effects, and signs of withdrawal in a cohort of neonates receiving dexmedetomidine, the majority of whom were receiving concomitant opioids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018812089DOI Listing
December 2018
2 Reads

Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials.

Ann Pharmacother 2018 Dec 2:1060028018817304. Epub 2018 Dec 2.

1 Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK, USA.

Objective: To evaluate clinical trials using bumetanide in autism spectrum disorder (ASD) treatment.

Data Sources: PubMed and Ovid MEDLINE (1946 to October 2018) were searched using terms bumetanide and autism. Bibliographies were reviewed for other relevant trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018817304DOI Listing
December 2018
3 Reads

Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?

Ann Pharmacother 2018 Dec 5:1060028018816466. Epub 2018 Dec 5.

4 Philadelphia College of Pharmacy, Philadelphia, PA, USA.

Objective: While improving glycemic control with antihyperglycemics has been demonstrated to reduce microvascular complications, the benefits of reduction in cardiovascular diseases (CVDs) have not been demonstrated with older agents. This article reviews current evidence of the CV outcomes of newer antihyperglycemics approved since 2008.

Data Sources: Peer-reviewed articles were identified from MEDLINE (1966 to October 31, 2018) using search terms exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, mortality, myocardial infarction (MI), heart failure (HF), and stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018816466DOI Listing
December 2018
12 Reads